Why Eli Lilly Bet on Triple Agonism (and What Comes After)

Tirzepatide was already the most effective approved obesity drug in the world when Eli Lilly decided to go further. Retatrutide — Lilly's triple agonist targeting GLP-1, GIP, and glucagon receptors — showed Phase 2 weight loss numbers that exceeded tirzepatide's SURMOUNT-1 results. In the background, orforglipron, an oral non-peptide GLP-1 agonist, was advancing through its own Phase 3 program.

The Eli Lilly retatrutide pipeline isn't just one drug. It's a portfolio strategy built on a specific thesis: that the injectable obesity market will stratify by efficacy and the oral market will open at scale, and that Lilly wants to win both.

Understanding that thesis explains why the company made the bets it did — and what comes after.

Tirzepatide Was Not the Endpoint

When tirzepatide's SURMOUNT-1 data landed in 2022, showing up to 20.9% weight loss at 72 weeks, it was the strongest efficacy signal the obesity drug class had produced. Semaglutide's STEP-1 trial showed 14.9% at 68 weeks. Tirzepatide had created a meaningful clinical gap.

Lilly could have consolidated around tirzepatide. Instead, they had already been developing retatrutide in parallel, based on a mechanistic hypothesis: if adding GIP to GLP-1 produced better outcomes than GLP-1 alone, what would adding glucagon do?

The glucagon receptor argument is specific. Glucagon primarily acts on the liver to release stored glucose. In the context of an obesity drug, activating the glucagon receptor simultaneously with GLP-1 and GIP creates additional metabolic effects:

• Increased hepatic fat oxidation
• Modest increase in resting energy expenditure
• Enhanced lipolysis (fat breakdown) in adipose tissue

The combination, at least theoretically, attacks obesity through more pathways than dual agonism — not just appetite suppression and insulin sensitization, but also direct fat metabolism. Phase 2 data supported the hypothesis: the 12 mg dose of retatrutide produced 24.2% mean body weight loss at 48 weeks in participants with obesity, with continued loss trajectory suggesting even higher numbers at 72 weeks.

What Orforglipron Adds to the Equation

Retatrutide requires injection, like tirzepatide and semaglutide. Orforglipron does not.

Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist — meaning it's a pill, taken once daily, that activates the GLP-1 receptor without the injection. This matters for two reasons.

Market expansion. A significant portion of people who could benefit from GLP-1 drugs decline injections. The needle aversion barrier isn't absolute — many people get comfortable with injections quickly — but it's real and it limits adoption. An oral GLP-1 with comparable efficacy to an injectable would reach a substantially different patient population.

Manufacturing economics. Peptide drugs (semaglutide, tirzepatide, retatrutide) require complex biologics manufacturing. Supply has been constrained for years — the Ozempic and Wegovy shortages of 2022–2024 were partly a manufacturing capacity problem. Small molecules are chemically synthesized at much lower per-unit cost and with more flexible manufacturing capacity. An oral small-molecule GLP-1 is cheaper to produce at scale than any injectable peptide.

Lilly's Phase 3 ACHIEVE program for orforglipron showed weight loss numbers in the 8–10% range at studied doses — lower than injectable tirzepatide, but potentially competitive with the lower-dose injectable GLP-1 range, and in oral form. That's a different product for a different patient profile, not a head-to-head replacement.

The Competitive Landscape Lilly Is Playing In

Eli Lilly isn't operating in isolation. The obesity drug market is the subject of one of the most intense pharmaceutical arms races in decades.

Novo Nordisk — tirzepatide's most direct competitor — has its own pipeline beyond semaglutide:

• CagriSema combines semaglutide with cagrilintide (an amylin analog). Phase 3 REDEFINE trials showed weight loss results comparable to or slightly exceeding tirzepatide, in the 22–25% range.
• Oral semaglutide (OIC-787, higher-dose oral formulation) is being developed to challenge the injectable-to-oral conversion Lilly is pursuing with orforglipron.

Amgen has AMG 133, a bispecific antibody targeting GLP-1 and GIP receptors — a different modality than a peptide agonist, potentially requiring monthly rather than weekly dosing.

Structure Therapeutics, Zealand Pharma, and Viking Therapeutics are each advancing compounds with differentiated targets, including glucagon receptor components.

The strategic picture: the first two years post-tirzepatide-launch were about proving the market. The next five years are about capturing it. Companies that can demonstrate clinical superiority at scale, manufacturing reliability, and formulary access will define who wins.

Lilly's bet is that retatrutide's superior efficacy will command premium positioning in the high-efficacy injectable segment, while orforglipron captures the oral/cost-sensitive segment. That's a two-axis strategy rather than a single-drug play.

The Retatrutide Risk Lilly Is Managing

Triple agonism adds efficacy, but it also adds complexity. The glucagon receptor activation that drives additional fat loss also has effects that need management:

• Increased heart rate. GLP-1 agonists generally increase resting heart rate by 5–10 bpm, and early retatrutide data suggested this effect was present. It's manageable, but it's a monitoring parameter in clinical trials and will likely inform prescribing guidance.
• Nausea profile. Triple agonism produces GI side effects similar to GLP-1 drugs, though the profile is not dramatically different from tirzepatide. Titration manages most of it.
• Glucose metabolism complexity. Glucagon increases blood glucose in fasting states; GLP-1 and GIP decrease it through insulin stimulation. The net effect appears glycemically acceptable in Phase 2 data, but it's a more complex pharmacodynamic interaction than dual agonism.

Regulators will scrutinize all three of these areas in the Phase 3 TRIUMPH program. The trial also needs to generate cardiovascular outcomes data sufficient to support labeling — a step that preceded Medicare coverage expansion for semaglutide.

What Comes After Retatrutide

The metabolic medicine pipeline beyond retatrutide involves two directions: combination approaches and downstream biology.

Combinations stack GLP-1/GIP/glucagon agonism with other hormonal targets. Amylin analogs (like cagrilintide), thyroid hormone receptor β agonists (for lipid and fat metabolism), and GLP-1/glucagon plus FGF21 receptor combinations are all in early or mid-stage development. The hypothesis is that targeting four or five metabolic axes simultaneously could push weight loss well past 30%.

Downstream biology approaches target mechanisms beyond hormonal signaling — adipose tissue biology, brown adipose tissue activation, and metabolic reprogramming at the mitochondrial level. These are earlier and less certain, but they represent where academic research is pointing.

Lilly's pipeline investments beyond retatrutide and orforglipron are not fully public, but the company has signaled continued investment in the obesity space — not a sign of a company that views current drugs as the endpoint.

Why This Matters for Patients Now

If you're choosing between tirzepatide and waiting for retatrutide, the calculus depends on your clinical situation. Tirzepatide is approved, accessible (with PA), and has a known safety and efficacy profile from SURMOUNT and the broader clinical experience. Retatrutide's Phase 2 results are compelling but Phase 3 data and FDA review add meaningful time before availability.

For someone with BMI in the high obesity range who hasn't responded adequately to semaglutide or tirzepatide, retatrutide represents a meaningful clinical step up that may not have a currently available equivalent. For someone who responds well to tirzepatide, the marginal benefit of waiting is less clear.

Orforglipron's oral profile will matter most for patients who decline injections — that's a distinct consideration from the efficacy discussion.

The lilly obesity drug pipeline post covers the regulatory timeline in more detail. For the mechanistic underpinning of why triple agonism produces more weight loss, see retatrutide metabolic effects.

Related reading

• What is retatrutide? The triple agonist explained
• Why retatrutide shows more weight loss than tirzepatide
• Retatrutide vs tirzepatide compared
• Retatrutide FDA approval timeline
• Tirzepatide: the complete guide